Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1 g - tablet, enteric coated - excipient ingredients: povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000 - salofalk tablets are indicated in the treatment of acute episodes and maintenance of remission of: i. mild to moderate ulcerative colitis; and ii. crohn?s ileitis and colitis

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose; hyprolose; microcrystalline cellulose - pryzex tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose; microcrystalline cellulose; magnesium stearate - pryzex tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose; hyprolose - pryzex tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; magnesium stearate - pryzex tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cinacalcet hydrochloride, quantity: 99.191 mg - tablet - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; povidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). cinacalcet viatris (cinacalcet hydrochloride tablets) should be used as adjunctive therapy.,cinacalcet viatris (cinacalcet hydrochloride tablets) is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cinacalcet hydrochloride, quantity: 66.127 mg - tablet - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). cinacalcet viatris (cinacalcet hydrochloride tablets) should be used as adjunctive therapy.,cinacalcet viatris (cinacalcet hydrochloride tablets) is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cinacalcet hydrochloride, quantity: 33.064 mg - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; povidone; magnesium stearate; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). cinacalcet viatris (cinacalcet hydrochloride tablets) should be used as adjunctive therapy.,cinacalcet viatris (cinacalcet hydrochloride tablets) is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose - indications: petibelle is indicated for use as an oral contraceptive.